Asterias Financial Statements From 2010 to 2022

Asterias Biotherapeutics financial statements provide useful quarterly and yearly information to potential Asterias Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Asterias Biotherapeutics financial statements helps investors assess Asterias Biotherapeutics' valuation, profitability, and current liquidity needs.
There are currently sixty-six fundamental signals for Asterias Biotherapeutics that can be evaluated and compared over time across rivals. Make sure you validate Asterias Biotherapeutics' prevailing fundamentals against the performance from 2010 to 2022 and make sure the trends continue to evolve in the right direction.
Asterias Biotherapeutics Tangible Asset Value is comparatively stable at the moment as compared to the past year. Asterias Biotherapeutics reported Tangible Asset Value of 41.55 Million in 2021. Working Capital is likely to gain to about 19 M in 2022, whereas Net Income Per Employee is likely to drop (888.7 K) in 2022.
  
Refresh
Check Asterias Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Asterias main balance sheet or income statement drivers, such as Direct Expenses of 147.2 K, Cost of Revenue of 203.4 K or Gross Profit of 2.5 M, as well as many exotic indicators such as Long Term Debt to Equity of 4.0E-4, PPandE Turnover of 0.79 or Receivables Turnover of 6.03. Asterias financial statements analysis is a perfect complement when working with Asterias Biotherapeutics Valuation or Volatility modules. It can also supplement various Asterias Biotherapeutics Technical models. Check out Trending Equities.

Asterias Biotherapeutics Revenues

3.58 Million

Share

Asterias Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets41.2 M38.8 M38.8 M
Increasing
Slightly volatile
Cash and Equivalents10.5 M11.9 M9.1 M
Increasing
Slightly volatile
Investments12.8 M15.7 M12.5 M
Increasing
Slightly volatile
Investments Current14.7 M15.3 M15.7 M
Increasing
Slightly volatile
Investments Non Current321.5 K374.4 K322.1 K
Increasing
Slightly volatile
Deferred Revenue2.2 M2.3 M2.5 M
Decreasing
Slightly volatile
Property Plant and Equipment Net5.6 M5.2 MM
Increasing
Slightly volatile
Tax Assets8.7 M8.8 M9.6 M
Decreasing
Slightly volatile
Trade and Non Trade Receivables492.4 K510.3 K529.6 K
Increasing
Slightly volatile
Trade and Non Trade Payables1.5 M1.5 M2.6 M
Decreasing
Slightly volatile
Goodwill and Intangible Assets25.4 M23.9 M22.4 M
Decreasing
Stable
Total Liabilities10.8 M8.6 M10.7 M
Increasing
Stable
Shareholders Equity30.4 M30.2 M28.2 M
Increasing
Slightly volatile
Accumulated Other Comprehensive Income421.4 K390.6 K69.3 K
Increasing
Slightly volatile
Current Assets21.8 M20.4 M20.7 M
Increasing
Slightly volatile
Assets Non Current26.7 M33.5 M26.1 M
Increasing
Slightly volatile
Current Liabilities4.2 MM5.1 M
Decreasing
Very volatile
Liabilities Non CurrentM10.5 M8.8 M
Increasing
Slightly volatile
Tax Liabilities10.4 M11.1 M10.9 M
Increasing
Slightly volatile
Total Debt29.5 K29.7 K32.5 K
Decreasing
Slightly volatile
Debt Current6.3 K6.3 K6.9 K
Decreasing
Slightly volatile
Debt Non Current23.3 K23.4 K25.6 K
Decreasing
Slightly volatile
Shareholders Equity USD43.8 M40.6 M31.1 M
Increasing
Slightly volatile
Cash and Equivalents USD10.9 M10.1 M7.3 M
Increasing
Slightly volatile
Total Debt USD29.5 K29.7 K32.5 K
Decreasing
Slightly volatile
Accounts Payable487 K360.9 K560 K
Decreasing
Slightly volatile
Receivables492.3 K510.3 K529.5 K
Increasing
Slightly volatile

Asterias Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues3.6 M3.6 M3.1 M
Increasing
Slightly volatile
Cost of Revenue203.4 K241.2 K194.4 K
Increasing
Slightly volatile
Selling General and Administrative Expense6.1 M7.1 M6.3 M
Increasing
Slightly volatile
Research and Development Expense12.8 M15.6 M12.7 M
Increasing
Slightly volatile
Operating Expenses18.9 M22.7 M19 M
Increasing
Slightly volatile
Interest Expense331.1 K306.9 K210.3 K
Increasing
Slightly volatile
Weighted Average Shares48.8 M45.2 M31.7 M
Increasing
Slightly volatile
Weighted Average Shares Diluted48.8 M45.2 M31.7 M
Increasing
Slightly volatile
Revenues USD2.7 M3.2 M2.6 M
Increasing
Slightly volatile
Gross Profit2.5 MM2.4 M
Increasing
Slightly volatile
Direct Expenses147.2 K148.5 K140.4 K
Increasing
Slightly volatile

Asterias Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Investment Acquisitions and Disposals11.3 M11.4 M12.5 M
Decreasing
Slightly volatile
Net Cash Flow from Financing14.5 M15.5 M13.2 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares21.4 M19.9 M13.5 M
Increasing
Slightly volatile
Net Cash Flow from Investing1.1 M830.3 K486.2 K
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents7.9 M7.3 M5.1 M
Increasing
Slightly volatile
Share Based Compensation3.5 M3.3 M2.6 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion2.8 M2.9 M2.8 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Gross Margin85.3286.3392.8725
Decreasing
Stable
Asset Turnover0.06520.06990.0551
Increasing
Slightly volatile
Sales per Share0.07840.07240.0719
Increasing
Slightly volatile
Price to Sales Ratio58.3144.7257.1097
Decreasing
Slightly volatile
Price to Book Value2.892.953.1419
Increasing
Very volatile
Debt to Equity Ratio6.0E-46.0E-40.0048
Decreasing
Slightly volatile
Current Ratio6.275.814.0376
Increasing
Slightly volatile
Book Value per Share1.161.07(22.0164)
Increasing
Slightly volatile
Tangible Assets Book Value per Share1.441.49.1431
Decreasing
Slightly volatile
Total Assets Per Share1.250.920.9762
Increasing
Stable
Receivables Turnover6.036.076.6341
Decreasing
Slightly volatile
PPandE Turnover0.790.730.8604
Decreasing
Stable
Cash and Equivalents Turnover0.390.280.3792
Decreasing
Slightly volatile
Accounts Payable Turnover4.684.934.1017
Increasing
Slightly volatile
Accrued Expenses Turnover1.431.441.5749
Decreasing
Slightly volatile
Long Term Debt to Equity4.0E-44.0E-40.0047
Decreasing
Slightly volatile
Quick Ratio3.183.562.9602
Increasing
Slightly volatile
Net Current Assets as percentage of Total Assets43.2540.09(4.3 K)
Increasing
Slightly volatile
Revenue to Assets0.07480.08440.0647
Increasing
Slightly volatile

Asterias Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization122.3 M133.1 M126.4 M
Increasing
Slightly volatile
Enterprise Value112.6 M121.8 M117 M
Increasing
Slightly volatile
Average Equity37.4 M38.8 M40.1 M
Increasing
Slightly volatile
Average Assets52.2 M52.7 M57.3 M
Decreasing
Slightly volatile
Invested Capital Average14 M14.1 M15.3 M
Decreasing
Stable
Tangible Asset Value44.8 M41.5 M31.5 M
Increasing
Slightly volatile
Working Capital19 M17.6 M12.1 M
Increasing
Slightly volatile
Revenue Per Employee103.1 K117.3 K92.3 K
Increasing
Slightly volatile

Asterias Fundamental Market Drivers

Average Daily Volume In Three Month13.94k
Fifty Day Average56.5550
Two Hundred Day Average46,394.2539

Asterias Upcoming Events

Upcoming Quarterly Report4th of April 2017
Next Financial Report15th of May 2017
Next Fiscal Quarter End31st of December 2016
Next Fiscal Year End4th of April 2017
Last Quarter Report30th of September 2016
Last Financial Announcement31st of December 2015

Asterias Biotherapeutics Investors Sentiment

The influence of Asterias Biotherapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Asterias. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Asterias Biotherapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Asterias Biotherapeutics' short interest history, or implied volatility extrapolated from Asterias Biotherapeutics options trading.

Current Sentiment - AST

Asterias Biotherapeutics Investor Sentiment

Greater number of Macroaxis users are presently bullish on Asterias Biotherapeutics. What is your sentiment towards investing in Asterias Biotherapeutics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Check out Trending Equities. Note that the Asterias Biotherapeutics information on this page should be used as a complementary analysis to other Asterias Biotherapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Tools for Asterias Stock

When running Asterias Biotherapeutics price analysis, check to measure Asterias Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Asterias Biotherapeutics is operating at the current time. Most of Asterias Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Asterias Biotherapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Asterias Biotherapeutics' price. Additionally, you may evaluate how the addition of Asterias Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
CEO Directory
Screen CEOs from public companies around the world
Go